ClinicalTrials.gg
Not yet recruitingNCT07862439BRITREUpdated Oct 14, 2026

Biomarker-guided Reduction of Immunosuppression in Liver Transplant Recipients (BRITRE)

A Phase 2 interventional study of miRNA Biomarker-Guided Immunosuppression Minimization and Conventional Biochemical Monitoring-Guided Immunosuppression Minimization in Liver Diseases, sponsored by University of Pennsylvania. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University of Pennsylvania · Phase 2, Interventional, and Treatment

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 369 studies in Liver Diseases with a site in United States — 46 open to participants now, 60 under way, 5 of them phase 3. Liver Diseases · United States.

Planned enrollment
41st of 270
180 · median 48
Started
2027
with 2 others
Phase 2
62 of 369
8 open now
Primary completion
2031-01
later than 53 of 58 live
Registered
368th of 369
by date

Among the 369 studies in Liver Diseases with a site in United States, this one is the 41st largest by planned enrollment of the 270 interventional ones that give a count, is one of 3 that started in 2027, is one of 62 in phase 2, reaches primary completion later than 53 of the 58 other live ones, and was the 368th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

46 of the 369 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 105 Liver Diseases studies recruiting now, 52 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

Researchers are interested in determining whether it is safe to reduce anti-rejection medication by approximately 50% after liver transplantation and whether special blood tests called biomarkers can identify early signs that the body is starting to attack the new liver before it gets hurt.

Read the detailed description

To evaluate the clinical utility of a miRNA-based signature for detecting alloimmune activation and early liver injury, when used in conjunction with conventional biochemical monitoring, to guide calcineurin (CNI) immunosuppression minimization in stable liver transplant recipients transplanted for non-immune liver diseases at least one year after transplantation. This is a multicenter, prospective, open-label, randomized controlled trial in stable liver transplant recipients receiving a CNI-based immunosuppression regimen. Participants will undergo closely monitored immunosuppression minimization with a target reduction of the CNI dose to 50% of the baseline maintenance dose.

Participants will be randomized in a 1:1 ratio to one of two immunosuppression minimization strategies: (1) guidance by a miRNA-based biomarker in conjunction with conventional biochemical monitoring, or (2) guidance by conventional biochemical monitoring alone.

03

Conditions studied

  • Liver Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years old.
  • >12 months and \< 24 months post transplantation.
  • Liver transplant for non-immune liver disease.
  • For participants with (history of HCV or donor with history of HCV): must be HCV PCR negative and have documented history of Sustained Viral Response to antiviral therapy (>=12 weeks) or documented, persistent spontaneous clearance of HCV.
  • For participants with : must be controlled with HBV antiviral treatment and anticipate receiving continuing HBV antiviral treatment for the duration of study participation.
  • Receiving maintenance IS with a CNI (tacrolimus, cyclosporin).
  • No history of BPAR in the prior 6 months.
  • Stable for the prior 3 months.
  • No history of chronic rejection.
  • No known clinical history of cirrhosis post-transplant.
  • Liver chemistry tests: total , , AST, GGT, and alkaline phosphatase all \<= for the prior 3 months.
  • Stable renal function, with >= 30 ml/min/1.73m2 by CKD-EPI (2021).
  • For participants known to have a history of TB or latent TB infection, documented history of completing appropriate treatment.
  • Participants of must have a negative pregnancy test upon study entry.
  • All participants with , must agree to use FDA approved methods of for the duration of the study (http://www.fda.gov/birthcontrol).
  • Vaccines up to date as per DAIT guidance for patients in interventional transplant trials of immunosuppression.

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness of a participant to give documented or comply with the study protocol.
  • History of retransplantation or multi-organ transplantation.
  • Split liver transplantation, except when involving a right tri-segment.
  • Liver transplantation indication of disease.
  • Use of mTOR inhibitor during the prior 3 months.
  • Any post-transplant diagnosis of (except basal cell carcinoma of skin) or recurrent hepatocellular carcinoma.
  • Active, uncontrolled systemic infection at enrollment.
  • Known history of infection with (HIV).
  • Pregnancy, breastfeeding, or plans to become pregnant during the study period.
  • History of mental illness or substance abuse that could impact study compliance, as judged by the investigator.
  • Any past or current medical history, physical examination findings, or laboratory test results not specified above, which, in the opinion of the investigator, may present additional risks, hinder compliance, or affect data quality or interpretation for this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    miRNA Biomarker-Guided Immunosuppression Minimization

    Participants undergo CNI dose reduction with immunosuppression minimization guided by a miRNA-based biomarker in conjunction with conventional biochemical monitoring.

    Other: miRNA Biomarker-Guided Immunosuppression Minimization

  • Active comparator
    Conventional Biochemical Monitoring-Guided Immunosuppression Minimization

    Participants undergo CNI dose reduction with immunosuppression minimization guided by conventional biochemical monitoring alone.

    Other: Conventional Biochemical Monitoring-Guided Immunosuppression Minimization

Interventions

  • OthermiRNA Biomarker-Guided Immunosuppression Minimization

    Participants undergo calcineurin inhibitor (CNI) dose reduction with immunosuppression minimization guided by a miRNA-based biomarker in conjunction with conventional biochemical monitoring.

  • OtherConventional Biochemical Monitoring-Guided Immunosuppression Minimization

    Participants undergo calcineurin inhibitor (CNI) dose reduction with immunosuppression minimization guided by conventional biochemical monitoring alone.

06

What researchers measure

Primary outcomes

  1. Successful 50% Immunosuppressive CNI reduction

    Successful 50% Immunosuppressive CNI reduction: Successful timepoint. protocol-directed 50% immunosuppression (IS) reduction up to the 12 month (\~52 week).

    Time frame: Up to 12months

  2. Allograft status: Rejection/graft loss

    Allograft status: Rejection/graft loss: Freedom from Rejection/graft loss for 12 months (\~52 weeks) after study enrollment. This endpoint will be the time to first occurrence of any of the following allograft (rejection or organ failure) events: * Biopsy-proven acute rejection (BPAR) * Clinical rejection (rejection treatment administered in the absence of BPAR) * Death or graft loss

    Time frame: 12 months after study enrollment

Secondary outcomes

  1. Decrease or improvement in renal function

    Decrease or improvement in renal function defined as: (baseline eGFR) - (eGFR at 1-year post-randomization).

    Time frame: 1 year post randomization

  2. For those with a baseline eGFR 30-90 mL/min/1.73 m2: absence of a 10% or greater decrease in eGFR

    • For those with a baseline eGFR 30-90 mL/min/1.73 m2: absence of a 10% or greater decrease in eGFR

    Time frame: 1 year post randomization

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2031, 48 months later.

Of 41 phase 2 interventional studies under Liver Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2031
CompletionEst.
Jan 2031
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 2 updates
  1. Oct 14, 2026
    Minor edits only
    + 1 other change: criteria formatting
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862439
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2031 (estimated)
Completion
Jan 2031 (estimated)
Last update
Oct 14, 2026

Study contacts

Miranda Targum, MHCI
Contact
miranda.targum@pennmedicine.upenn.edu
215-217-7054
Tracia Debnam, MS
Contact
tracia.debnam@nih.gov
Abraham Shaked, MD, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion